- Home
- CRL vs NUVL Comparison
CRL vs NUVL Comparison
Compare CRL & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRL
- NUVL
- Stock Information
- Founded
- CRL 1947
- NUVL 2017
- Country
- CRL United States
- NUVL United States
- Employees
- CRL N/A
- NUVL N/A
- Industry
- CRL Biotechnology: Commercial Physical & Biological Resarch
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- CRL Health Care
- NUVL Health Care
- Exchange
- CRL Nasdaq
- NUVL Nasdaq
- Market Cap
- CRL 7.3B
- NUVL 6.5B
- IPO Year
- CRL 2000
- NUVL 2021
- Fundamental
- Price
- CRL $198.10
- NUVL $93.54
- Analyst Decision
- CRL Buy
- NUVL Strong Buy
- Analyst Count
- CRL 16
- NUVL 11
- Target Price
- CRL $190.86
- NUVL $120.00
- AVG Volume (30 Days)
- CRL 1.0M
- NUVL 485.9K
- Earning Date
- CRL 11-05-2025
- NUVL 11-11-2025
- Dividend Yield
- CRL N/A
- NUVL N/A
- EPS Growth
- CRL N/A
- NUVL N/A
- EPS
- CRL N/A
- NUVL N/A
- Revenue
- CRL $4,028,615,000.00
- NUVL N/A
- Revenue This Year
- CRL N/A
- NUVL N/A
- Revenue Next Year
- CRL $2.43
- NUVL N/A
- P/E Ratio
- CRL N/A
- NUVL N/A
- Revenue Growth
- CRL N/A
- NUVL N/A
- 52 Week Low
- CRL $91.86
- NUVL $55.54
- 52 Week High
- CRL $230.02
- NUVL $99.94
- Technical
- Relative Strength Index (RSI)
- CRL 76.81
- NUVL 60.16
- Support Level
- CRL $184.88
- NUVL $90.00
- Resistance Level
- CRL $174.73
- NUVL $99.94
- Average True Range (ATR)
- CRL 5.97
- NUVL 4.20
- MACD
- CRL 2.36
- NUVL 0.30
- Stochastic Oscillator
- CRL 95.23
- NUVL 64.33
About CRL Charles River Laboratories International Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.